Quality of Care in For-profit and Not-for-profit Health Plans Enrolling Medicare Beneficiaries
Overview
Affiliations
Background: For-profit health plans now enroll the majority of Medicare beneficiaries who select managed care. Prior research has produced conflicting results about whether for-profit health plans provide lower quality of care.
Objective: The objective was to compare the quality of care delivered by for-profit and not-for-profit health plans using Medicare Health Plan Employer Data and Information Set (HEDIS) clinical measures.
Research Design: This was an observational study comparing HEDIS scores in for-profit and not-for-profit health plans that enrolled Medicare beneficiaries in the United States during 1997.
Outcome Measures: Outcome measures included health plan quality scores on each of 4 clinical services assessed by HEDIS: breast cancer screening, diabetic eye examination, beta-blocker medication after myocardial infarction, and follow-up after hospitalization for mental illness.
Results: The quality of care was lower in for-profit health plans than not-for-profit health plans on all 4 of the HEDIS measures we studied (67.5% vs 74.8% for breast cancer screening, 43.7% vs 57.7% for diabetic eye examination, 63.1% vs 75.2% for beta-blocker medication after myocardial infarction, and 42.1% vs 60.4% for follow-up after hospitalization for mental illness). Adjustment for sociodemographic case-mix and health plan characteristics reduced but did not eliminate the differences, which remained statistically significant for 3 of the 4 measures (not beta-blocker medication after myocardial infarction). Different geographic locations of for-profit and not-for-profit health plans did not explain these differences.
Conclusion: By using standardized performance measures applied in a mandatory measurement program, we found that for-profit health plans provide lower quality of care than not-for-profit health plans. Special efforts to monitor and improve the quality of for-profit health plans may be warranted.
Pharmaceutical policies: effects of regulating drug insurance schemes.
Pantoja T, Penaloza B, Cid C, Herrera C, Ramsay C, Hudson J Cochrane Database Syst Rev. 2022; 5:CD011703.
PMID: 35502614 PMC: 9062704. DOI: 10.1002/14651858.CD011703.pub2.
Geissler K, Cooper M, Zeber J Adm Policy Ment Health. 2021; 48(4):718-728.
PMID: 33438094 DOI: 10.1007/s10488-020-01106-2.
Behavioral Health Care Quality Among Marketplace Insurers in 2019.
Abraham J, Cai S, Anderson D, Drake C Psychiatr Serv. 2020; 72(2):200-203.
PMID: 33334154 PMC: 7855409. DOI: 10.1176/appi.ps.202000115.
Leopold S Clin Orthop Relat Res. 2018; 476(10):1906-1909.
PMID: 30179938 PMC: 6259860. DOI: 10.1097/CORR.0000000000000432.
Du J, Rascoe A, Marcus R Clin Orthop Relat Res. 2018; 476(10):1910-1919.
PMID: 30001293 PMC: 6259823. DOI: 10.1097/CORR.0000000000000394.